Diagnosis of Helicobacter pylori after triple therapy in uncomplicated duodenal ulcers - A cost-effectiveness analysis

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 4, 2000, Pages 433-442

  Gene E ^a   Calvet, X ^a   Azagra, R ^b  

^a Hospital Universitari Parc Taulí   (Spain)

^b DAP Cerdanyola ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CARBON 13; CLARITHROMYCIN; OMEPRAZOLE; OXYTETRACYCLINE; UREA;

ARTICLE; BREATH ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DUODENUM ULCER; DYSPEPSIA; FOLLOW UP; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL;

BREATH TESTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG THERAPY, COMBINATION; DUODENAL ULCER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; UREA;

EID: 0034090488     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00735.x     Document Type: Article

References (46)

1. 1 Lindell G, Celebioglu F, von Stael Holstein C. On the natural history of peptic ulcer. Scand J Gastroenterol 1994; 29: 979-82.
2. 2 Kurata JH, Nogawa AN, Abbey DE, Petersen F. A prospective study of risk for peptic ulcer disease in Seventh-day Adventists. Gastroenterology 1992; 102: 902-9.
3. 3 Bonnevie O. The incidence of duodenal ulcer in Copenhagen county. Scand J Gastroenterol 1975; 10: 385-93.
4. 4 Sonnenberg A, Schwartz JS, Cutler AF, Vakil N, Bloom BS. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. Arch Intern Med 1998; 158: 852-60.
5. 5 Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995; 155: 922-8.
6. 6 Taylor JL, Zagari M, Murphy K, Freston JW. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med 1997; 157: 87-97.
7. 2-antagonist maintenance therapy versus Helicobacter pylori eradication in patients with chronic duodenal ulcer disease: a prospective study. Aliment Pharmacol Ther 1998; 12: 873-80.
8. 8 Duggan AE, Tolley K, Hawkey CJ, Logan RFA. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model. Br Med J 1998; 316: 1648-54.
9. 9 Phull PS, Halliday D, Price AB, Jacyna MR. Absence of dyspeptic symptoms as a test of Helicobacter pylori eradication. Br Med J 1996; 312: 349-50.
10. 10 McColl KE, El-Nujumi A, Murray LS, et al. Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer. Gut 1998; 42: 618-22.
11. 11 Calvet X. Tratamiento de la infectión por Helicobacter pylori. Gastroenterol Hepatol 1998; 21: 203-6.
12. 12 Worku ML, Sidebotham RL, Karim QN. Effects of ranitidine bismuth citrate on Helicobacter pylori motility, morphology and survival. Aliment Pharmacol Ther 1999; 13: 753-60.
13. 13 Bardhan KD. The role of proton pump inhibitors in the treatment of gastro-esophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 15-25.
14. 14 Comet R, Calvet X, Navarro M, Garcia N, Sanfeliu I. Seven-day therapy with omeprazole, clarithromycin and amoxicillin for treatment of Helicobacter pylori infection. Gastroenterol Hepatol 1998; 21: 81-3.
15. 15 Nogués I, Carrillo R, Cerain MJ, et al. Tratamiento erradicador del Helicobacter pylori en el ulcus péptico activo: ¿Vamos hacia la pauta de seis días? Aten Primaria 1998; 20 (Suppl. 1): 331(Abstract).
16. 16 Huelin J, Jimenez M, Sanchez Galdon S, et al. Short-course treatment to eradicate H. pylori in 246 patients with peptic ulcer disease. Gut 1997; 41(Suppl 1): A105(Abstract).
17. 13C] urea breath test to confirm eradication of Helicobacter pylori. Am J Gastroenterol 1995; 90: 224-6.
18. 18 Rollan A, Giancaspero R, Arrese M, et al. Accuracy of invasive and non-invasive tests to diagnose Helicobacter pylori infection after antibiotic treatment. Am J Gastroenterol 1997; 92: 1268-74.
19. 19 Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52.
20. 20 O'Connor HJ. Eradication of Helicobacter pylori: therapies and clinical implications. Postgrad Med J 1992; 68: 549-57.
21. 21 Fendrick AM, Chey WD, Margaret N, Palaniappan J, Fennerty MB. Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease. Am J Med 1999; 107: 133-6.
22. 22 Petersen H, Kristensen P, Johannesen T. The natural course of peptic ulcer disease and its predictors. Scand J Gastroenterol 1995; 30: 17-24.
23. 23 de Boer WA, Tytgat GN. 90% cure: which anti-Helicobacter therapy can achieve this treatment goal? Am J Gastroenterol 1995; 90: 1381-2.
24. 24 Brullet E, Calvet X, Campo R, Rue M, Catot L, Donoso L. Factors predicting failure of endoscopie injection therapy in bleeding duodenal ulcer. Gastrointest Endosc 1996; 43: 111-6.
25. 25 Ordre de 27 de Setembre de 1997, per la qual s'aproven els preus publics corresponents als serveis que presta l'Institut Català de la Salut. Diari Oficial de la Generalitat de Catalunya 1997; 2505: 12-149.
26. 26 Severens JL, Laheij RJF, Jansen JBMJ, Van der Lisdonk EH, Verbeek ALM. Estimating the cost of lost productivity in dyspepsia. Aliment Pharmacol Ther 1998; 12: 919-23.
27. 27 Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol 1999; 94: 725-9.
28. 28 Pasta DJ, Taylor JL, Henning JM. Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter pylori. Med Decis Making 1999; 19: 353-63.
29. 29 van der Hulst RW, Rauws EA, Koycu B, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology 1997; 113: 1082-6.
30. 30 Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-9.
31. 31 Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of Helicobacter pylori reduces the rate of re-bleeding in peptic ulcer disease. Scand J Gastroenterol 1993; 28: 939-42.
32. 32 Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. J Am Med Assoc 1996; 275: 622-9.
33. 33 The European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
34. 34 Rodriguez M, Lite J, Forne M, et al. Susceptibilidad antibiótica de Helicobacter pylori. Gastroenterol Hepatol 1997; 20: 93 (Abstract).
35. 35 Paoluzi P, Rossi P, Consolazio A, et al. A single-blind, monocentric study of four treatments for H. pylori eradication: an interim report. Gastroenterology 1998; 114: A252-3 (Abstract).
36. 36 Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. Metaanalisis sobre la comparación de 7 vs. 10 vs. 14 días de terapia triple para el tratamiento de la infección por H. pylori. Gastroenterol Hepatol 1999; 22: 554(Abstract).
37. 37 Sierra E, Sicilia B, Revillo MJ, et al. Alto índice de fracaso de un tercer intento de erradicación guiado por cultivo: resultados preliminares de un estudio prospectivo. Gastroenterol Hepatol 1999; 22: 552(Abstract).
38. 38 Labenz J, Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994; 55: 19-23.
39. 39 Santander C, Gravalos RG, Gomez Cedenilla A, Cantero J, Pajares JM. Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Am J Gastroenterol 1996; 91: 1549-52.
40. 40 Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996; 110: 72-83.
41. 41 Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Immediate endoscopy or initial Helicobacter pylori serological testing for suspected peptic ulcer disease: estimating cost-effectiveness using decision analysis. Yale J Biol Med 1996; 69: 187-95.
42. 42 Ofman JJ, Rabeneck L. The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review. Am J Med 1999; 106: 335-46.
43. 43 Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12: 823-37.
44. 44 Ducons JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollon F. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999; 13: 775-80.
45. 45 Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7.
46. 46 Gisbert JP, Pajares JM, Garcia-Valriberas R, et al. Recurrence of Helicobacter pylori infection after eradication: incidence and variables influencing it. Scand J Gastroenterol 1998; 33: 1144-51.